Navignostics is a Swiss clinical diagnostics and research company founded in 2022 as a spin-off from the University of Zurich Bodenmiller Lab. Headquartered in Horgen, Switzerland, we bring together scientists, lab technicians, software developers and business experts to advance precision oncology.

Our mission is to enable personalized cancer treatment by analyzing tumor tissue and identifying the most effective therapies for individual patients, and by supporting drug developers in selecting the right patient populations for clinical trials.

We combine highly multiplex protein imaging with advanced data analytics to deliver a spatial single-cell proteomics approach validated through over a decade of translational and clinical research. Our services include diagnostic analyses for clinicians and translational research support for biomarker identification and participant selection in trials.

We partner with hospitals, research institutions and biotech companies to translate complex spatial proteomic data into actionable treatment decisions and to accelerate development of targeted therapies.